Profile data is unavailable for this security.
About the company
Glenmark Pharmaceuticals Limited is an India-based global pharmaceutical company. The Company is focused on building a global formulation business with branded, generics and over the counter (OTC) segments in the therapy areas of dermatology, respiratory and oncology. The Company also has a regional/country-specific presence in other therapeutic areas like diabetes, cardiovascular and oral contraceptives. Its product portfolio includes topical products, liquids, respiratory MDI/DPI, complex injectables and biologics, and oral solids. The Company has a bioequivalent version of Tiotropium Bromide dry powder inhaler (DPI) under the brand, Tiogiva in the United Kingdom and Tavulus in Spain, for the treatment of chronic obstructive pulmonary disease. Ryaltris, the Company's first branded specialty product globally, is a fixed dose combination nasal spray that combines an antihistamine (Olopatadine) with a steroid (Mometasone Furoate) for treatment of allergic rhinitis.
- Revenue in INR (TTM)118.13bn
- Net income in INR-18.99bn
- Incorporated1977
- Employees15.56k
- LocationGlenmark Pharmaceuticals LtdB D S MargChakala, Off Western Express HighwayAndheri (E),MUMBAI 400099IndiaIND
- Phone+91 2 240189999
- Fax+91 2 240189986
- Websitehttps://glenmarkpharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alembic Pharmaceuticals Ltd | 62.29bn | 6.16bn | 211.69bn | 14.86k | 34.36 | 4.39 | 23.83 | 3.40 | 31.34 | 31.34 | 317.00 | 245.12 | 0.9865 | 1.10 | 6.01 | 4,192,105.00 | 9.75 | 10.72 | 12.92 | 14.25 | 72.46 | 65.98 | 9.89 | 12.47 | 0.9863 | 11.56 | 0.0963 | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Suven Pharmaceuticals Ltd | 10.51bn | 3.00bn | 222.06bn | 1.05k | 73.89 | 10.83 | 62.57 | 21.12 | 11.81 | 11.81 | 41.34 | 80.56 | 0.4983 | 1.64 | 8.58 | 9,993,856.00 | 14.23 | 23.17 | 15.19 | 26.20 | 57.34 | 58.85 | 28.56 | 33.21 | 9.64 | 47.59 | 0.0307 | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
| Natco Pharma Ltd. | 39.99bn | 13.88bn | 225.74bn | 3.98k | 16.30 | 3.85 | 14.33 | 5.65 | 77.30 | 77.30 | 222.76 | 326.99 | 0.6366 | 0.9929 | 3.91 | -- | 22.10 | 12.33 | 25.46 | 14.25 | 82.08 | 76.47 | 34.72 | 25.16 | 3.42 | 81.49 | 0.0596 | -- | 47.72 | 13.81 | 94.09 | 16.59 | -5.76 | -- |
| Pfizer Ltd | 21.93bn | 5.51bn | 232.58bn | 1.70k | 42.19 | 6.47 | 37.90 | 10.60 | 120.52 | 120.52 | 479.40 | 785.95 | 0.533 | 1.86 | 12.93 | -- | 13.40 | 14.22 | 15.69 | 17.71 | 63.86 | 61.79 | 25.14 | 24.05 | 4.27 | 37.18 | 0.0256 | 23.74 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
| Laurus Labs Ltd | 50.41bn | 1.61bn | 246.40bn | 6.01k | 153.72 | 5.99 | 44.57 | 4.89 | 2.97 | 2.97 | 93.32 | 76.27 | 0.6282 | 1.38 | 3.11 | 8,391,593.00 | 2.10 | 10.13 | 3.21 | 16.47 | 51.75 | 47.63 | 3.34 | 12.83 | 0.6393 | 2.22 | 0.3851 | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| J B Chemicals and Pharmaceuticals Ltd | 34.84bn | 5.53bn | 280.52bn | 5.10k | 51.45 | 9.60 | 40.60 | 8.05 | 35.13 | 35.13 | 221.51 | 188.36 | 0.9232 | 2.53 | 5.52 | -- | 14.64 | 15.77 | 18.04 | 18.89 | 66.07 | 62.03 | 15.86 | 16.06 | 1.56 | 17.11 | 0.1144 | 32.31 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
| Ajanta Pharma Ltd | 42.09bn | 8.16bn | 285.38bn | 7.84k | 35.27 | 8.07 | 29.99 | 6.78 | 64.79 | 64.79 | 334.10 | 283.31 | 0.9034 | 1.30 | 3.65 | 5,365,515.00 | 17.52 | 16.61 | 22.41 | 20.47 | 74.66 | 73.22 | 19.39 | 19.31 | 2.12 | -- | 0.0098 | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
| IPCA Laboratories Ltd | 77.07bn | 5.47bn | 311.36bn | 17.34k | 56.88 | 4.92 | 35.12 | 4.04 | 21.58 | 21.58 | 303.80 | 249.59 | 0.7814 | 1.20 | 5.64 | 4,446,155.00 | 5.37 | 10.33 | 7.51 | 13.52 | 66.58 | 59.16 | 6.87 | 12.25 | 1.28 | 13.12 | 0.1569 | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
| Gland Pharma Ltd | 56.65bn | 7.72bn | 331.11bn | 4.59k | 42.86 | 3.79 | 29.64 | 5.85 | 46.89 | 46.89 | 343.86 | 529.65 | 0.5828 | 1.21 | 4.12 | -- | 7.95 | 13.23 | 8.92 | 14.56 | 61.64 | 55.88 | 13.64 | 22.92 | 2.85 | 37.73 | 0.0409 | -- | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
| Glenmark Pharmaceuticals Ltd | 118.13bn | -18.99bn | 398.83bn | 15.56k | -- | 5.08 | -- | 3.38 | -67.28 | -53.21 | 418.40 | 278.11 | 0.7004 | 1.81 | 4.28 | -- | -10.86 | 1.02 | -15.92 | 1.43 | 62.64 | 61.27 | -15.50 | 1.43 | 0.8447 | 1.19 | 0.1356 | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
| GlaxoSmithKline Pharmaceuticals Limited | 34.54bn | 5.90bn | 434.30bn | 3.21k | 73.62 | 24.43 | 65.84 | 12.57 | 34.82 | 34.82 | 203.88 | 104.93 | 1.00 | 2.71 | 16.67 | 10,755,860.00 | 17.14 | 11.01 | 29.26 | 17.88 | 61.36 | 55.77 | 17.08 | 12.25 | 1.49 | 466.45 | 0.0104 | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
Data as of Jul 23 2024. Currency figures normalised to Glenmark Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
20.97%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 30 Jun 2024 | 9.33m | 3.31% |
| Capital Research & Management Co. (World Investors)as of 30 Jun 2024 | 8.82m | 3.13% |
| HSBC Global Asset Management (Hong Kong) Ltd.as of 06 Apr 2023 | 8.60m | 3.05% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 6.36m | 2.26% |
| Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2023 | 6.27m | 2.22% |
| The Vanguard Group, Inc.as of 04 Jul 2024 | 5.64m | 2.00% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 30 Jun 2024 | 4.24m | 1.50% |
| NTAsset (Thailand) Co., Ltd.as of 30 Jun 2023 | 4.13m | 1.46% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 3.33m | 1.18% |
| Invesco Asset Management (India) Pvt Ltd.as of 30 Jun 2024 | 2.45m | 0.87% |
More ▼
Data from 31 Dec 2021 - 15 Jul 2024Source: FactSet Research Systems Inc.
